Reviews

 
Recommend
Trust
Listening
 
« 1 2 »
Page 2 of 2
 
Written by a patient at Northampton General Hospital
7th July 2017


Today I have been given the all clear of neck cancer following radiotherapy treatment under the watchful eye of Dr Qurrat Mehmood. I couldn't have wished for a doctor to be more comforting, reassuring and empathetic, she is a credit to her profession and I am so grateful to her.

Recommend
Trust
Listening
 
Written by a patient at Northampton General Hospital
24th May 2017


Dr Mehmood treated me for Head and Neck cancer at Northampton General and was an absolute delight to work with. Good humour and very well trained. Totally recommend

Recommend
Trust
Listening
 
 

« 1 2 »
Page 2 of 2

Profile

Dr Qurrat van den Blink is a Consultant Clinical Oncologist specialising in Lung cancer, head and neck cancer and body stereotactic radiotherapy for various tumour sites.


Dr Qurrat graduated from Liverpool University medical School in 2003 obtaining a MBCHB with honours.

She completed specialist training in Clinical Oncology in the Northwest, based at the Christie Hospital, Manchester and Rosemere Cancer centre in Preston.

In 2013 Dr Qurrat undertook a clinical research fellowship at The Princess Margaret Cancer centre in Toronto, gaining clinical expertise in lung cancer radiotherapy , image guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT) and stereotactic radiotherapy for lung cancer and lung metastases.

The research projects included a review of outcomes for stereotactic radiotherapy in lung metastases and the use of PET imaging during chemoradiotherapy for lung cancer.

Dr Qurrat has continued to develop her skills in body stereotactic radiotherapy and undertook further experience in June 2015 at Princess Margaret Cancer centre, Toronto.

As a Consultant working at Northampton General hospital and Univeristy Hospitals of Leicester , she is skilled and experienced in delivering stereotactic radiotherapy for metastatic disease in the lung, liver, nodes, bones and spine for all tumour sites and providing chemotherapy and radiotherapy for lung and head and neck cancers.